Asian Venture Capital Journal (AVCJ)
Top stories
China's Meituan-Dianping raises $4b in new round
Meituan-Dianping, China's largest online-to-offline (O2O) local services platform, has raised $4 billion in a Series C round of funding led by existing investor Tencent Holdings.
Deal focus: Lalamove seeks edge in last-mile delivery
Shunwei Capital has led a $100 million round for Hong Kong-based delivery start-up Lalamove with a view to supporting its expansion in the competitive mainland China market
Intel Capital announces China, Japan investments
Intel Capital, the captive VC arm of Intel Corp, has invested in technology start-ups from China and Japan as part of a $60 million overall investment in 15 companies worldwide.
News continued
Analysis
Southeast Asia VC: Growth impediment?
Southeast Asia has an abundance of local players targeting early-stage deals while foreign investors fly in to participate in the later stage rounds. The industry is looking for ways to fill the hole in the middle
Upcoming events
AVCJ Private Equity & Venture Forum - ESG Forum 2017
November 13 2017, Central, Hong Kong
More information
30th Annual Private Equity & Venture Forum - Hong Kong 2017
November 14 2017, Central, Hong Kong
More informationInterviews
Q&A: Zhong Lun's Yun Zhou
Yun Zhou, a partner with Chinese law firm Zhong Lun, discusses the effects of Chinese government guidelines on outbound investment in terms of who will be doing these deals, and how
Q&A: Hamilton Lane's Hartley Rogers
Hartley Rogers, chairman of Hamilton Lane, discusses how the global fundraising boom reflects a larger private equity investment opportunity and why LPs are honing their approaches to the asset class
People
Ex-Headland partner joins China growth investor CRE Alliance
William Shen, formerly head of Greater China at Headland Capital Partners, has become CEO of CRE Alliance, a private equity joint venture between China Resources Enterprise (CRE) and Great Wall Asset Management.
C-Bridge hires ex-GSK executive as senior partner
C-Bridge Capital, a Chinese healthcare-focused private equity firm, has appointed Abbas Hussain, who was most recently global president for pharmaceuticals and vaccines at GlaxoSmithKline (GSK), as a senior partner.
